MiCheck Archives - We are Minomic

Exciting Milestone for Minomic: MiCheck® Prostate Receives PLA Code Assignment!

by Minomic | Jul 30, 2025

We are proud to announce that the American Medical Association (AMA) has accepted our PLA Code application for MiCheck® Prostate. This next-generation blood test helps urologists identify the risk of clinically significant prostate cancer. Effective October 1, 2025,...

Minomic Inc Ushers in a New Era of Growth in U.S. with Sushmita Utpala as CEO of Minomic Inc!

by Minomic | Mar 20, 2025

We are thrilled to announce a significant milestone in Minomic’s journey: the appointment of Sushmita Utpala as our new Minomic Inc.’s Chief Executive Officer! After a period of dedicated preparation, we are eager to share this exciting news and the vision that...

Asia Summit on Global Health in Hong Kong

by Minomic | May 17, 2024

David Burdis is attending the Asia Summit on Global Health in Hong Kong as part of the Investment NSW delegation. During this event, he has been able to present the benefits of MiCheck® Prostate to numerous interested parties including Professor Chung-Mau Lo, HK...

New Peer-Reviewed Paper on MiCheck^® Prostate

by Minomic | Oct 5, 2023

Minomic is pleased to announce the publication of the company’s latest research paper supporting the utilisation of MiCheck® Prostate as an aid to diagnosing clinically significant prostate cancer. It is clear there is strong clinical need to identify those patients...

Dr Brad Walsh’s interview on Australia’s leading business and finance streaming service AusBiz

by Minomic | Oct 3, 2023

Last Thursday Dr Brad Walsh was interviewed on Australia’s leading business and finance streaming service, AusBiz by renowned TV personality David Koch about Minomic’s technology and future plans as a fitting end to Prostate Cancer Awareness Month. You can view...

Minomic International Ltd Receives Reimbursement for MiCheck^® Prostate in the USA

by Minomic | Sep 28, 2023

Thursday 28 September, Sydney, Australia Sydney-based biotech Minomic International Ltd is delighted to announce that the company’s ground-breaking test for prostate cancer, MiCheck® Prostate, has received its first reimbursement in the United States from the Centres...

« Older Entries

PUBLICATIONS

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis. Sayyadi, N, Justiniano, I, Wang, Y, Zheng, X, Zhang, W, Jiang, L, Polikarpov, DM, Willows, RD, Gillatt, D, Campbell, D, Walsh, BJ, Yuan, J, Lu, Y, Packer, NH, Wang, Y & Piper, JA 2022. Scientific Reports, vol. 12, no. 1, 18452.

Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. Zhang, W, Campbell, DH, Walsh, BJ, Packer, NH, Liu, D & Wang, Y 2022. Journal of Nanobiotechnology, vol. 20, no. 1, 446.

Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Wei Zhang, Ling Wang, Dan Li, Douglas H. Campbell, Bradley J. Walsh, et al. RSC. 2022.

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate